Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Rare Diseases

Syndrome

Leukemia

Preleukemia

Myelodysplastic Syndromes

Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Acute Disease

Neoplasms by Histologic Type

Hematologic Diseases

Bone Marrow Diseases

Precancerous Conditions

Disease Attributes

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Acute Graft Versus Host Disease

Lymphosarcoma

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

CAR-T cells combined with Eps8 peptide specific dendritic cell,or CAR-T cells combined with WT1 peptide specific dendritic cell

After pretreatment, chimeric antigen receptor T cells will be transfused.

Chimeric antigen receptor T cells

After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.

peptide specific dendritic cell

Sanfang Tu, M.D, Ph.D

Yanjie He, M.D, Ph.D

Yuhua Li, M.D, Ph.D

The main purpose of this study is to verify the safety and potential effectiveness of CART cells combined with peptide specific dendritic cell in relapsed/refractory leukemia.

A prospective study to evaluate the safety and efficacy of Chimeric antigen receptor T cells combined with Eps8 or WT1（Wilms tumor 1） peptide specific dendritic cell for patients with relapsed/refractory leukemia. There are options for CAR-targets: CD19, CD20, CD22 and CD10 for acute lymphoblastic leukemia; CD33, CD38 CD56, CD117, CD123, CD34 and Muc1 for acute myeloid leukemia and Myelodysplastic Syndrome. Progression free survival, overall Survival, overall response rate, and duration of response were monitored.

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic Syndromes

Incidence and severity of cytokine release syndrome(CRS): The systemic inflammatory response in patients with significantly increased IL-6 and other cytokines during the observation period is defined as CRS, which is divided into 1-5 grades, 1-2 Grade is mild, grade 3-5 is severe

Time from random to the first occurrence of disease progression.

Time from randomization to death due to any cause

The proportion of the total number of patients with complete remission and partial remission (CR+PR) after treatment in the total number of evaluable cases

During the observation period, the time between complete remission of bone marrow (the ratio of bone marrow blast cells is less than 5%) to the recurrence of bone marrow (the ratio of bone marrow blast cells is greater than 5%) is the continuous remission time.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS	NCT03291444	Leukemia, Acute... Leukemia, Acute... Myelodysplastic...	Chimeric antige... peptide specifi...	18 Years - 80 Years	Zhujiang Hospital
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS	NCT03291444	Leukemia, Acute... Leukemia, Acute... Myelodysplastic...	Chimeric antige... peptide specifi...	18 Years - 80 Years	Zhujiang Hospital
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS	NCT03291444	Leukemia, Acute... Leukemia, Acute... Myelodysplastic...	Chimeric antige... peptide specifi...	18 Years - 80 Years	Zhujiang Hospital

Spots Global Cancer Trial Database for peptide specific dendritic cell